A Phase 1 First-In-Human Study Of The Anti-Cd38 Dimeric Fusion Protein Tak-169 For The Treatment Of Patients (Pts) With Relapsed Or Refractory Multiple Myeloma (Rrmm) Who Are Proteasome Inhibitor (Pi)- And Immunomodulatory Drug ( Imid)-Refractory, Including Pts Relapsed/Refractory (R/R) Or Naive To Daratumumab (Dara)